Key result
Cleveland Clinic continuous-flow total artificial heart develops right pump impeller thrombosis in animal models.
In vivo animal testing of the Cleveland Clinic continuous-flow total artificial heart identified thrombotic depositions on the right impeller, providing data for computational fluid dynamics and design optimization.
The development of total artificial heart devices is a complex undertaking that includes chronic biocompatibility assessment of the device. It is considered particularly important to assess whether device design and features can be compatible long term in a biological environment. As part of the development program for the Cleveland Clinic continuous-flow total artificial heart (CFTAH), we evaluated the device for signs of thrombosis and biological material deposition in four animals that had achieved the intended 14-, 30-, or 90-day durations in each respective experiment. Explanted CFTAHs were analyzed for possible clot buildup at "susceptible" areas inside the pump, particularly the right pump impeller. Depositions of various consistency and shapes were observed. We here report our findings, along with macroscopic and microscopic analysis post explant, and provide computational fluid dynamics data with its potential implications for thrombus formation.
No takes yet. Share an insight, caveat, or question.
Karimov et al. (2016) studied this question. Cleveland Clinic continuous-flow total artificial heart (CFTAH) was evaluated on Thrombosis and biological material deposition. Evaluation of the Cleveland Clinic continuous-flow total artificial heart in four animals over 14 to 90 days revealed thrombotic depositions of various consistency and shapes on the right pump impeller.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: